



# Q1 2020 Financial Results

As of March 31, 2020 | Reported On May 7, 2020

# Safe Harbor Statement

Certain statements contained in this presentation are "forward-looking statements." We have tried to identify these forward-looking statements by using words such as "may," "might," "will," "expect," "anticipate," "believe," "could," "intend," "plan," "estimate," "should," "if," "project," and similar expressions. All statements other than statements of historical facts contained in this presentation, including statements regarding our growth strategies, our vision, future operations, future financial position, future revenue, projected costs, prospects, plans, objectives of management and expected market growth and potential are forward-looking statements. We have based these forward-looking statements on our current expectations and projections about future events. However, these forward-looking statements are subject to risks, uncertainties, assumptions and other factors that may cause our actual results, performance or achievements to be materially different from our expectations and projections. Some of these risks, uncertainties and other factors are set forth in this presentation and in other documents that we file with the United States Securities and Exchange Commission (the "SEC"), including those described in "Risk Factors" in our Annual Report on Form 10-K for the year ended December 31, 2019 filed with the SEC on or around March 6, 2020, as it may be revised or updated in our subsequent filings. These risk factors include, but are not limited to, the continuing impact of the COVID-19 outbreak on the economy and our operations (including temporary clinic closures, shortened business hours and reduced patient demand) our failure to develop or acquire company-owned or managed clinics as rapidly as we intend, our failure to profitably operate company-owned or managed clinics. Given these risks and uncertainties, readers are cautioned not to place undue reliance on our forward-looking statements. Projections and other forward-looking statements included in this presentation have been prepared based on assumptions, which we believe to be reasonable, but not in accordance with U.S. Generally Accepted Accounting Principals ("GAAP") or any guidelines of the SEC. Actual results may vary, perhaps materially. You are strongly cautioned not to place undue reliance on such projections and other forward-looking statements. All subsequent written and oral forward-looking statements attributable us or to persons acting on our behalf are expressly qualified in their entirety by these cautionary statements. Except as required by federal securities laws, we disclaim any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Any such forward-looking statements, whether made in this presentation or elsewhere, should be considered in the context of the various disclosures made by us.

## **Accounting Adjustments Related to the Consolidation of the Operations of the PCs**

In those states which require a licensed Doctor of Chiropractic to own the entity that offers chiropractic services, the Company enters into a management agreement with a professional corporation (PC) licensed in that state to provide chiropractic services. To increase transparency into operating results and to align with accounting rules, the Company will now consolidate the full operations of the PC. This will result in increases to our revenue and G&A expenses by an identical amount and would have no impact on our bottom line except in instances when the PC has sold treatment packages and wellness plans. Revenue from these packages and plans will now be deferred and will be recognized when patients use their visits. The Company has previously consolidated its clinic operations in Non-PC states such as Arizona and New Mexico, and the deferred revenue around packages and plans in those states was already reflected in its financial statements. Therefore, these adjustments are isolated to the managed clinics in PC states. These adjustments will have no impact on cash flow.

## **Business Structure**

The Joint Corp. is a franchisor of clinics and an operator of clinics in certain states. In Arkansas, California, Colorado, District of Columbia, Florida, Illinois, Kansas, Kentucky, Maryland, Massachusetts, Michigan, Minnesota, New Jersey, New York, North Carolina, Oregon, Pennsylvania, Rhode Island, South Dakota, Tennessee, Washington, West Virginia and Wyoming, The Joint Corp. and its franchisees provide management services to affiliated professional chiropractic practices.



# Our Mission is to Improve Quality of Life through Routine and Affordable Chiropractic Care

**24%**

Increase in system-wide sales Q1 2020 over Q1 2019

**15%**

Increase in comp sales<sup>1</sup> for clinics >13 months in operation Q1 2020 over Q1 2019

**10%**

Increase in comp sales<sup>1</sup> for clinics >48 months in operation Q1 2020 over Q1 2019

**Q1 2020 vs Q1 2019**

Revenue

\$13.6M  
up 28%

Net Income

\$815k  
vs \$953k

Adjusted EBITDA<sup>2</sup>

\$1.7M,  
up \$0.1M

*Unrestricted cash \$10.7M at Mar. 31, 2020, compared to \$8.5M at Dec. 31, 2019*




<sup>1</sup>Comparable sales include only the sales from clinics that have been open at least 13 or 48 full months and exclude any clinics that have permanently closed, but include clinics that are temporarily closed due to COVID-19. | <sup>2</sup> Reconciliation of Adjusted EBITDA to GAAP earnings is included in the Appendix.

# Continued Clinic Growth

Opened another greenfield in February 2020, bringing the corporate portfolio count to 61

## Total Clinics Open


■ Franchise ■ Company Owned/Managed




# Increased RDs to 22 in March 2020

Pipeline of 200+ Undeveloped Licenses & LOIs at March 31, 2020


**% of Sales  
by Regional Developers**



**Franchise Licenses  
Sold Annually**



**Gross Cumulative  
Franchise Licenses Sold<sup>1</sup>**



- 79% of clinics supported by RDs
- RDs cover 57% of Metropolitan Statistical Areas (MSAs) in the US



<sup>1</sup> Of the 865 franchise licenses sold as of March 31, 2020, 212 are in active development, 530 are currently operating and the balance represents terminated/closed licenses.

# COVID-19 Response

## Preparing for the Challenge

- Increasing communication to franchisees and clinic teams
- Instituting a COVID internal hotline
- Enhancing clinic sanitation and cleanliness policies & procedures
- Adapting content marketing
- Improving access to key PPE and cleaning supplies

## Supporting Franchisees

- Waiving the minimum royalty requirement for all franchises for the remainder of 2020
- Waiving the minimum local ad spend requirement through the end of Q2
- Waiving the monthly tech fee for clinics closed 16 days or more in that month

## Franchisee Communication Feedback Survey

- 88% either very positive or mostly positive about their association with The Joint
- 90% either extremely confident or somewhat confident about the future of the business

# Q1 2020 Financial Results

<i>\$ in M<sup>1</sup></i>	Q1 2020	Q1 2019	Increases	
Revenue	\$13.6	\$10.7	\$2.9	28%
• Corporate clinics	7.3	5.6	1.7	29%
• Franchise fees	6.4	5.1	1.3	26%
Cost of revenue	1.5	1.2	0.3	23%
Sales and marketing	2.1	1.5	0.5	36%
Depreciation	0.7	0.4	0.3	79%
G&A	8.7	6.7	2.0	31%
Net Income / (Loss)	0.8	1.0	(0.2)	-14%
Adj. EBITDA <sup>2</sup>	1.7	1.6	0.1	5%



<sup>1</sup> Due to rounding, numbers may not add up precisely to the totals.

<sup>2</sup> Reconciliation of Adjusted EBITDA to GAAP earnings is included in the Appendix.


# Business Model Continues to Drive Long-term Growth

People will continue to seek more noninvasive, holistic ways in which to manage their pain.

We will be ready to treat them.

The Joint Corp. 9-yr. CAGR 77%<sup>1</sup> vs. Industry CAGR 1.2%<sup>2\*</sup>

System-wide Gross Sales  
(\$ in M)



<sup>1</sup> For the period ended Dec. 31, 2019 | <sup>2</sup> IBIS World Chiropractors Market Research Report; February 2019 \* and 5-year CAGR




# Non-GAAP Measure Definition

This presentation includes a presentation of EBITDA and Adjusted EBITDA, which are non-GAAP financial measures. EBITDA and Adjusted EBITDA are presented because they are important measures used by management to assess financial performance, as management believes they provide a more transparent view of the Company's underlying operating performance and operating trends than GAAP measures alone. Reconciliations of net loss to EBITDA and Adjusted EBITDA are presented where applicable. The Company defines EBITDA as net income before net interest, tax expense, depreciation, and amortization expenses. The Company defines Adjusted EBITDA as EBITDA before acquisition-related expenses, bargain purchase gain, loss on disposition or impairment, and stock-based compensation expenses.

EBITDA and Adjusted EBITDA do not represent and should not be considered alternatives to net income or cash flows from operations, as determined by accounting principles generally accepted in the United States, or GAAP. While EBITDA and Adjusted EBITDA are frequently used as measures of financial performance and the ability to meet debt service requirements, they are not necessarily comparable to other similarly titled captions of other companies due to potential inconsistencies in the methods of calculation. EBITDA and Adjusted EBITDA should be reviewed in conjunction with the Company's financial statements filed with the SEC.

# Q1 2020 Segment Results



<b>Total Revenues</b>	
<b>Total Operating Costs</b>	
<b>Operating Income (Loss)</b>	
<b>Other Income (Expense), net</b>	
<b>Loss Before Income Tax Expense</b>	
<b>Total Income Taxes</b>	
<b>Net Income (Loss)</b>	
<b>Net Interest</b>	
<b>Income Taxes</b>	
<b>Total Depreciation and Amortization Expense</b>	
<b>EBITDA</b>	
<b>Stock Based Compensation Exp</b>	
<b>Bargain Purchase Gain</b>	
<b>Loss on Disposition/Impairment</b>	
<b>Acquisition Expenses</b>	
<b>Adjusted EBITDA</b>	

	<b>Corporate Clinics</b>	<b>Franchise Operations</b>	<b>Unallocated Corporate</b>	<b>The Joint Consolidated</b>
Total Revenues	\$ 7,294	\$ 6,350	\$ 0	\$ 13,644
Total Operating Costs	(6,510)	(3,506)	(2,875)	(12,891)
Operating Income (Loss)	784	2,844	(2,875)	753
Other Income (Expense), net	(1)	3	(6)	(4)
Loss Before Income Tax Expense	783	2,847	(2,881)	749
Total Income Taxes	-	-	(66)	(66)
Net Income (Loss)	783	2,847	(2,815)	815
Net Interest	1	(3)	6	4
Income Taxes	-	-	(66)	(66)
Total Depreciation and Amortization Expense	578	0	76	654
EBITDA	1,361	2,845	(2,798)	1,408
Stock Based Compensation Exp	1	5	245	250
Bargain Purchase Gain	-	-	-	-
Loss on Disposition/Impairment	1	-	-	1
Acquisition Expenses	-	-	-	-
Adjusted EBITDA	1,363	2,849	(2,553)	1,659

# GAAP – Non-GAAP Reconciliation

	Q1-18	Q2-18	Q3-18	Q4-18	FY18	Q1-19	Q2-19	Q3-19	Q4-19	FY19	Q1-20
Total Revenue	8,647	8,805	9,242	9,968	36,662	10,679	11,170	12,726	13,875	48,451	13,644
Total Cost of Revenue	972	1,052	1,085	1,202	4,310	1,206	1,299	1,427	1,634	5,566	1,486
<b>Gross Profit</b>	<b>\$ 7,675</b>	<b>\$ 7,753</b>	<b>\$ 8,157</b>	<b>\$ 8,767</b>	<b>\$ 32,351</b>	<b>\$ 9,473</b>	<b>\$ 9,871</b>	<b>\$ 11,300</b>	<b>\$ 12,241</b>	<b>\$ 42,885</b>	<b>\$ 12,158</b>
Sales & Marketing	1,102	1,294	1,195	1,229	4,820	1,506	1,769	1,793	1,845	6,914	2,055
Depreciation/Amortization Expense	387	405	389	375	1,556	366	404	538	591	1,899	654
Other Operating Expenses	6,269	6,119	6,820	6,625	25,833	6,658	7,209	8,324	8,465	30,656	8,695
Total Other Income (Expense)	(11)	19	(11)	(31)	(34)	8	(15)	(20)	(16)	(43)	(4)
Total Income Taxes	(63)	6	(50)	70	(38)	(1)	10	7	33	49	(66)
<b>Net Income (Loss)</b>	<b>\$ (32)</b>	<b>\$ (51)</b>	<b>\$ (208)</b>	<b>\$ 437</b>	<b>\$ 147</b>	<b>\$ 953</b>	<b>\$ 462</b>	<b>\$ 617</b>	<b>\$ 1,292</b>	<b>\$ 3,324</b>	<b>\$ 815</b>
Net Interest	11	11	11	14	47	12	15	17	18	62	4
Income Taxes	(63)	6	(50)	70	(38)	(1)	10	7	33	49	(66)
Depreciation and Amortization Expense	387	405	389	375	1,556	366	404	538	591	1,899	654
<b>EBITDA</b>	<b>\$ 303</b>	<b>\$ 371</b>	<b>\$ 142</b>	<b>\$ 895</b>	<b>\$ 1,712</b>	<b>\$ 1,329</b>	<b>\$ 892</b>	<b>\$ 1,179</b>	<b>\$ 1,934</b>	<b>\$ 5,333</b>	<b>\$ 1,408</b>
Stock Based Compensation	208	139	123	159	628	172	179	186	184	721	250
Bargain Purchase Gain	-	(30)	-	17	(13)	(19)	-	-	-	(19)	-
Loss on Disposition/Impairment	0	251	343	-	595	105	(18)	30	(2)	114	1
Acquisition Expenses	-	3	1	-	4	(0)	3	33	11	47	-
<b>Adjusted EBITDA</b>	<b>\$ 511</b>	<b>\$ 734</b>	<b>\$ 609</b>	<b>\$ 1,072</b>	<b>\$ 2,926</b>	<b>\$ 1,586</b>	<b>\$ 1,056</b>	<b>\$ 1,428</b>	<b>\$ 2,126</b>	<b>\$ 6,196</b>	<b>\$ 1,659</b>

# The Joint Corp. Contact Information



Peter D. Holt, President and CEO

[peter.holt@thejoint.com](mailto:peter.holt@thejoint.com)

The Joint Corp. | 16767 N. Perimeter Dr., Suite 110, Scottsdale, AZ 85260 | (480) 245-5960



Jake Singleton, CFO

[jake.singleton@thejoint.com](mailto:jake.singleton@thejoint.com)

The Joint Corp. | 16767 N. Perimeter Dr., Suite 110, Scottsdale, AZ 85260 | (480) 245-5960



Kirsten Chapman, LHA Investor Relations

[thejoint@lhai.com](mailto:thejoint@lhai.com)

LHA Investor Relations | One Market Street, Spear Tower, Suite 3600, San Francisco, CA 94105 | (415) 433-3777



[@thejointchiro](https://www.facebook.com/thejointchiro)



[@thejointchiro](https://twitter.com/thejointchiro)



[@thejointcorp](https://www.youtube.com/thejointcorp)